Literature DB >> 18408925

Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability.

Michael M Schmidt1, Greg M Thurber, K Dane Wittrup.   

Abstract

Theoretical analyses suggest that the cellular internalization and catabolism of bound antibodies contribute significantly to poor penetration into tumors. Here we quantitatively assess the internalization of antibodies and antibody fragments against the commonly targeted antigen carcinoembryonic antigen (CEA). Although CEA is often referred to as a non-internalizing or shed antigen, anti-CEA antibodies and antibody fragments are shown to be slowly endocytosed by LS174T cells with a half-time of 10-16 h, a time scale consistent with the metabolic turnover rate of CEA in the absence of antibody. Anti-CEA single chain variable fragments (scFvs) with significant differences in affinity, stability against protease digestion, and valency exhibit similar uptake rates of bound antibody. In contrast, one anti-CEA IgG exhibits unique binding and trafficking properties with twice as many molecules bound per cell at saturation and significantly faster cellular internalization after binding. The internalization rates measured herein can be used in simple computational models to predict the microdistribution of these antibodies in tumor spheroids.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18408925      PMCID: PMC2840397          DOI: 10.1007/s00262-008-0518-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  40 in total

1.  Computational model for effects of ligand/receptor binding properties on interleukin-2 trafficking dynamics and T cell proliferation response.

Authors:  E M Fallon; D A Lauffenburger
Journal:  Biotechnol Prog       Date:  2000 Sep-Oct

2.  Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention.

Authors:  Christilyn P Graff; K Dane Wittrup
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

3.  Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C.

Authors:  Christilyn P Graff; Kerry Chester; Richard Begent; K Dane Wittrup
Journal:  Protein Eng Des Sel       Date:  2004-04-28       Impact factor: 1.650

4.  High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

Authors:  G P Adams; R Schier; A M McCall; H H Simmons; E M Horak; R K Alpaugh; J D Marks; L M Weiner
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

5.  Specificities and binding properties of eight monoclonal antibodies against carcinoembryonic antigen.

Authors:  A Hedin; S Hammarström; A Larsson
Journal:  Mol Immunol       Date:  1982-12       Impact factor: 4.407

Review 6.  Delivery of molecular and cellular medicine to solid tumors.

Authors:  R K Jain
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

7.  Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies.

Authors:  T M Behr; M Béhé; M Löhr; G Sgouros; C Angerstein; E Wehrmann; K Nebendahl; W Becker
Journal:  Eur J Nucl Med       Date:  2000-07

8.  Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.

Authors:  R Stein; M Juweid; M J Mattes; D M Goldenberg
Journal:  Cancer Biother Radiopharm       Date:  1999-02       Impact factor: 3.099

9.  Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.

Authors:  Surinder K Sharma; R Barbara Pedley; Jeetendra Bhatia; Geoffrey M Boxer; Ethaar El-Emir; Uzma Qureshi; Berend Tolner; Helen Lowe; N Paul Michael; Nigel Minton; Richard H J Begent; Kerry A Chester
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

10.  Reversible dimer formation and stability of the anti-tumour single-chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopy.

Authors:  Yie Chia Lee; Mark K Boehm; Kerry A Chester; Richard H J Begent; Stephen J Perkins
Journal:  J Mol Biol       Date:  2002-06-28       Impact factor: 5.469

View more
  40 in total

Review 1.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

2.  Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.

Authors:  Katie F Maass; Chethana Kulkarni; Alison M Betts; K Dane Wittrup
Journal:  AAPS J       Date:  2016-02-24       Impact factor: 4.009

3.  Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models.

Authors:  Joseph Ryan Polli; Frank A Engler; Joseph P Balthasar
Journal:  J Pharm Sci       Date:  2018-10-12       Impact factor: 3.534

4.  A mechanistic compartmental model for total antibody uptake in tumors.

Authors:  Greg M Thurber; K Dane Wittrup
Journal:  J Theor Biol       Date:  2012-09-06       Impact factor: 2.691

5.  Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin.

Authors:  Rahul Palchaudhuri; Borja Saez; Jonathan Hoggatt; Amir Schajnovitz; David B Sykes; Tiffany A Tate; Agnieszka Czechowicz; Youmna Kfoury; Fnu Ruchika; Derrick J Rossi; Gregory L Verdine; Michael K Mansour; David T Scadden
Journal:  Nat Biotechnol       Date:  2016-06-06       Impact factor: 54.908

6.  Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors.

Authors:  Feng Wang-Johanning; Kiera Rycaj; Joshua B Plummer; Ming Li; Bingnan Yin; Katherine Frerich; Jeremy G Garza; Jianjun Shen; Kevin Lin; Peisha Yan; Sharon A Glynn; Tiffany H Dorsey; Kelly K Hunt; Stefan Ambs; Gary L Johanning
Journal:  J Natl Cancer Inst       Date:  2012-01-12       Impact factor: 13.506

7.  Dose dependence of intratumoral perivascular distribution of monoclonal antibodies.

Authors:  John J Rhoden; Karl Dane Wittrup
Journal:  J Pharm Sci       Date:  2011-11-04       Impact factor: 3.534

Review 8.  Engineered antibodies for molecular imaging of cancer.

Authors:  Anna M Wu
Journal:  Methods       Date:  2013-10-01       Impact factor: 3.608

Review 9.  Affinity and avidity in antibody-based tumor targeting.

Authors:  Stephen I Rudnick; Gregory P Adams
Journal:  Cancer Biother Radiopharm       Date:  2009-04       Impact factor: 3.099

Review 10.  Ligand-targeted theranostic nanomedicines against cancer.

Authors:  Virginia J Yao; Sara D'Angelo; Kimberly S Butler; Christophe Theron; Tracey L Smith; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Andrey S Dobroff; C Jeffrey Brinker; Andrew R M Bradbury; Wadih Arap; Renata Pasqualini
Journal:  J Control Release       Date:  2016-01-06       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.